Related Experiment Video
Updated: May 6, 2026

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
Incident Stroke in Pediatric Sickle Cell Anemia Despite Overall Improved Transcranial Doppler Velocity in a Ugandan
Bill Wambaka1, Amiirah Mpungu1, Vincent Mboizi1
1Global Health Uganda, Kampala, Uganda.
Insights
Transcranial Doppler ultrasound (TCD) screening for stroke risk in children with sickle cell anemia (SCA) may be less effective in Uganda. Additional factors like anemia and low fetal hemoglobin (HbF) also contribute to stroke risk.
Area of Science:
- Pediatric Neurology
- Hematology
- Global Health
Background:
- Stroke is a major complication of sickle cell anemia (SCA) in children.
- Transcranial Doppler (TCD) ultrasound is used for primary stroke prevention in high-resource settings.
- Identifying stroke risk factors in low-resource regions like Uganda is crucial.
Purpose of the Study:
- To evaluate stroke risk factors in Ugandan children with SCA.
- To assess the effectiveness of TCD screening in this population.
- To investigate the role of hydroxyurea (HU) therapy in brain protection.
Main Methods:
- A 30-month open-label, single-arm trial of dose-escalated hydroxyurea in Ugandan children (3-9 years) with SCA.
- Included clinical assessments, TCD, and laboratory tests.
- Prospective monitoring for stroke events.
Main Results:
- 15.7% of 264 children had abnormal TCD at enrollment.
- Four children without abnormal TCD developed stroke within 16 months.
- Stroke risk factors included low fetal hemoglobin (HbF ≤3.1%), hypoxemia, and severe anemia.
Conclusions:
- TCD screening alone may not fully identify high stroke risk in Uganda.
- Anemia, low HbF, hypoxemia, and infections are significant stroke contributors.
- Primary stroke prevention from early childhood and continuous hydroxyurea therapy are recommended.
Introduction:
Transcranial Doppler ultrasound (TCD) screening for primary stroke prevention in children with sickle cell anemia (SCA) was established in higher-resource regions, targeting interventions for highest velocity ("abnormal"). We sought to identify additional stroke risk factors in Uganda.
Methods:
We conducted a 30-month open-label single-arm Ugandan hydroxyurea trial, dose-escalated to maximum-tolerated dose, aimed to test brain protection for children aged 3-9 years with SCA. Study procedures included history, clinical stroke examination, and prospective TCD and laboratory assessments.
Results:
Overall, 264 children received study HU, mean age 5.6 ± 1.7, hemoglobin 7.8 ± 1.2 g/dL, fetal hemoglobin (HbF) 11.9% ± 8.1%, enrolment TCD mean TAMV 148.4 ± 29.3 cm/sec; 15 (5.7%) had abnormal TCD. The mean TAMV at trial completion was 131.9 ± SD 25.7 cm/sec. Four participants without abnormal enrolment TCD developed acute stroke within the initial 16 months (incidence 0.62 per 100 person-years): two had enrolment HbF ≤3.1%, two had low oxygen saturation (90%), and one had recurring severe anemia necessitating multiple transfusions. Apparent stroke precipitants were severe malaria, acute chest syndrome, recent pain crisis, or uncertain cause. At trial completion, eight additional participants had a higher risk TCD category than at enrolment.
Conclusion:
The effectiveness of TCD screening for stroke prevention may vary by region, as no participant with an incident stroke was at the highest risk. Antecedent and/or ongoing SCA-related risks of anemia, low HbF, hypoxemia, infections, and/or disease complications likely contributed to stroke despite trial HU. Results suggest that TCD alone may not fully identify the highest stroke risk in the region, and there is a need for primary stroke prevention from early childhood and continuous hydroxyurea therapy.
More Related Videos
05:23Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
07:24A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Ischemic Stroke l: Introduction
Ischemic Stroke ll: Pathophysiology
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology